How to make a great scientific presentation, delivered as a webinar for the NIHR Emergency Care Incubator in winter 2022.

1. SCIENTIFIC
PRESENTATIONS
M A K I N G G R E A T
R I C K B O D Y

2. RULES OF A GREAT PRESENTATION
VICTORIA BRAZIL
Connect with
your
audience
Look and
sound great
Keep it simple

3. MESSAGE
P1
P3
PRESENTATIONS
MEDIA
P2
DELIVERY
P3

4. TELL A STORY

5. WHAT’S DIFFERENT
ABOUT SCIENTIFIC
PRESENTATIONS?

6. Introduction, Objectives, Methods, Results, Conclusions
THE STRUCTURE IS OFTEN ALREADY SET
SPECIFIC
CONSIDERATIONS
Because the subject is ‘dry’ & the format is rigid
IT IS OFTEN HARD TO TELL A STORY
It can be challenging to be engaging while still
presenting data in sufficient detail for critical appraisal
IT IS HARD TO PRESENT DATA NICELY

7. CONSIDERATIONS AROUND
P1: THE MESSAGE
Still tell a story
Still start with
the bottom line
Still connect with
the audience
Still keep it
simple

8. CONSIDERATIONS AROUND
P2: THE MEDIA
Colours
Theme Fonts

9. PRESENTING DATA
Identify the key messages
Cut out everything unnecessary
Be creative to make data accessible & appealing

10. EXAMPLES

11. What does the NIHR fund?
Research
infrastructure
Research
programmes &
projects
Research training
& fellowships

12. What is an
NIHR Incubator?
"Networking structures to support
capacity building and
multidisciplinary career
development in priority areas
where critical mass is low"
NIHR Strategic Review of Training 2017

13. Challenging
Cardiovascular
Cases
Can The Guidelines
Solve Them?
@richardbody

14. When to
suspect
HOCM
ECG changes
Short PR interval
Heart block
Left ventricular hypertrophy
Precordial T wave inversion
Extreme axis
Normal in 6% of cases
Symptoms
Chest pain, often exertional,
after alcohol or after meals
Heart failure
Unexplained syncope
Palpitations

15. ESCAPE FROM THE LABORATORY
ESCAPE FROM THE LABORATORY
FACT OR FICTION?
HS-TROPONIN

16. WE CAN
WE CAN RAPIDLY
RAPIDLY RULE OUT MI
RULE OUT MI
With ONE TEST on
arrival...
Using cutoffs around
the limit of detection
With TWO TESTS 1-3
hours apart...
Using a validated
algorithm
WITH LABORATORY HIGH-
SENSITIVTY TROPONIN ASSAYS
ALSO with ONE test
on arrival...
Using decision aids
like HEART, T-MACS,
EDACS

18. ESC Guidelines 2020: 0/1h algorithm for ruling in/out myocardial infarction
Collet et al, European Heart Journal, 2020

19. Very low or
low and no 1h delta
Other High or 1h delta
Rule out Observe Rule in
THE0/1HRULEIN/OUTALGORITHM
Collet et al, Eur Heart J, 2020

20. Very low or
low and no 1h delta
Other High or 1h delta
Rule out Observe Rule in
Good evidence base
Short interval between serial tests
Lab turnaround time too long
All patients will get two tests
THE0/1HRULEIN/OUTALGORITHM
Collet et al, Eur Heart J, 2020

21. Collet et al, Eur Heart J, 2020
Very low or
low and no 1h delta
Other
High and/or
1h delta
RULE OUT
RULE OUT RULE IN
RULE IN
OBSERVE
OBSERVE
Stress test OR CTCA OR
angiography OR none
Discharge OR Admit

23. Adults presenting to the ED
with symptoms of venous
thromboembolism
TRIAL
DESIGN
Aim was to enrol 1,000
patients
Assessed with Wells score

24. TRIAL DESIGN
SCREENING
Approach
Check eligibility
Written informed consent
SAMPLING FOLLOW-UP
Venous blood sample
Capillary samples
90-day follow-up
CRF completed
Centrifuged within 4 hours
Analysed centrally

25. Trial Sites
Manchester
Salford
St George’s
University College Hospital London
Royal London Hospitals
Homerton University Hospitals
Addenbrookes
South Warwickshire
Royal Infirmary of Edinburgh
St John’s Hospital, Livingston
Queen Elizabeth, Glasgow
UKE Hamburg

26. Trial Sites
St John's Hospital, Livingston
Royal Infirmary Edinburgh
Queen Elizabeth University
Hospital Glasgow
Manchester University NHS Foundation Trust
(Prof Rick Body, Chief Investigator)
Salford Royal NHS Foundation Trust
South Warwickshire NHS Foundation Trust
Addenbrookes, Cambridge
Royal London
St George's
University College London Hospitals
UKE Hamburg

28. 1
2
3
Individual RCT
N=629, all with normal ECGs
Control: Standard care (local pathway)
Intervention: Rule out if hs-cTn (various) below
limit of detection
LoDED
TRIAL
Primary outcome:
Discharge within 4 hours with
no MACE at 30 days
No significant difference
between groups
46% vs 37% discharged
Adjusted odds ratio 1.58
(95% CI 0.84 to 2.98).
https://heart.bmj.com/content/106/20/1586
Abbreviations: RCT, randomized controlled trial
MACE, major adverse cardiac events
(death, acute myocardial infarction or urgent coronary revascularization)

30. VERSUS

31. Factors associated with first-pass success:
(After propensity score matching)
Video vs direct laryngoscopy
19,071 intubations in the National
Emergency Airway Registry (US)
88% with at least one difficult airway characteristic
Video laryngoscopy
OR 2.2 (95% CI 1.6 - 2.9)
Impression of difficult airway
OR 0.7 (95% CI 0.5 - 0.99)
Blood/vomit in airway
OR 0.5 (95% CI 0.4 - 0.8)
External laryngeal manipulation
OR 0.4 (95% CI 0.3 - 0.5)
Trent et al,
Ann Emerg Med 2021

33. F
e
m
a
l
e
H
y
p
e
r
l
i
p
i
d
a
e
m
i
a
H
y
p
e
r
t
e
n
s
i
o
n
D
i
a
b
e
t
e
s
P
r
i
o
r
m
y
o
c
a
r
d
i
a
l
i
n
f
a
r
c
t
i
o
n
F
a
m
i
l
y
h
i
s
t
o
r
y
o
f
h
e
a
r
t
d
i
s
e
a
s
e
C
u
r
r
e
n
t
s
m
o
k
i
n
g
80%
60%
40%
20%
0%
Baselinecharacteristics
817 patients; 121 (14.8%) had type 1 or type 2 AMI
Mean age 63.9 years (SD 15.1)

34. F
e
m
a
l
e
H
y
p
e
r
l
i
p
i
d
a
e
m
i
a
H
y
p
e
r
t
e
n
s
i
o
n
D
i
a
b
e
t
e
s
P
r
i
o
r
m
y
o
c
a
r
d
i
a
l
i
n
f
a
r
c
t
i
o
n
F
a
m
i
l
y
h
i
s
t
o
r
y
o
f
h
e
a
r
t
d
i
s
e
a
s
e
C
u
r
r
e
n
t
s
m
o
k
i
n
g
80%
60%
40%
20%
0%
Baselinecharacteristics
817 patients; 121 (14.8%) had type 1 or type 2 AMI
Mean age 63.9 years (SD 15.1)

35. Methods
Prospective diagnostic test accuracy study
12 hospitals and four ambulance NHS trusts
We included patients with suspected cardiac chest pain presenting within 12
hours of symptom onset
We excluded patients with STEMI and those without capacity to provide written
informed consent
Verbal consent was taken initially, followed by written consent in hospital
Blood was drawn from IV cannulae in the ambulance and taken to hospital to be
tested for troponin with the Roche cobas h232 point of care testing device within
4 hours
Paramedics prospectively collected data for the T-MACS and HEART scores
Leftover plasma was centrifuged and frozen at -80 degrees Celsius pending
future analysis

36. CONSENT Consultation with NARSG*
Consultation with a patient group
Verbal consent
in the ambulance
Written consent
in the hospital
*: NARSG: National Ambulance Research Steering Group

37. SAMPLES
Paramedics drew blood from IV cannulae
Point of care tests were run in hospital
(Roche Cobas h232)
Remaining plasma frozen for batch testing at
a later date

38. INDEXTEST
Roche Cobas h232 cardiac
troponin, with and without
T-MACS and the HEART
score

39. Let’s say we have to summarise the
results of four RCTs of DOACs vs warfarin
for VTE in one slide

40. Edoxaban
Dabigatran
DOACS for treatment of vte
Comparison: Warfarin. Outcome: Efficacy
Rivaroxaban
Apixaban
Non-inferior
Non-inferior
Non-inferior
Non-inferior

41. Templates
Stock images, icons
Pro features
www.Canva.com

44. You may have to use PowerPoint to
present
FORMATTING
TIPS
If so, be sure to check your slides.
They may not look the same after
inserting from other software
To escape formatting errors,
download slides as PNG files and
insert into blank slides

45. CONSIDERATIONS AROUND
P3: DELIVERY
Rehearse
Script Record

46. RULES OF A GREAT PRESENTATION
VICTORIA BRAZIL
Connect with
your
audience
Look and
sound great
Keep it simple